DEA Registers More Than 900 Medical Marijuana Dispensaries in a First

The Drug Enforcement Administration on Friday issued its first federal registrations to more than 900 state-licensed medical marijuana dispensaries, giving operators in seven states a formal place inside the Controlled Substances Act's regulatory system for the first time. The registrations went to dispensaries in Alabama, Florida, Mississippi, South Dakota, Texas, Virginia and West Virginia, the Justice Department said in a release announcing the action.

The step is the opening phase of an order Attorney General Todd Blanche signed April 23 under 21 U.S.C. § 811(d), a provision that allows the attorney general to place defined drug activities under controls consistent with U.S. treaty obligations. Under the order, qualifying medical marijuana businesses operate under Schedule III rules while marijuana outside that definition remains on Schedule I, the strictest tier.

"The American people deserve access to the best medical treatments in the world," Blanche said in the release. "The regulated distribution of medical marijuana by the applicants that have been granted registration by the Drug Enforcement Administration will help ensure broader access to chronic pain treatment and the safety of the American people."

What the registration grants, and what it requires

A state license did not guarantee federal registration. DEA said each dispensary had to pass its pre-registration investigation and had to operate under a state medical marijuana framework the agency judged consistent with federal law and treaty obligations. Registered businesses are now subject to federal security, recordkeeping and inventory requirements that apply to handlers of scheduled substances.

Manufacturers and distributors — the businesses that supply dispensaries — are still under review. Their applications, DEA said, need additional scrutiny that includes facility inspections, production controls and quota determinations. Applicants that filed inside the order's initial 60-day window and whose paperwork is still pending may keep transacting with other qualified applicants and with newly registered businesses while they wait.

DEA described the rollout as phased and said it will keep processing applications. The release did not say how many dispensaries applied, how the agency split the initial registrations among the seven states, or how many applications were rejected.

The chronic pain argument the department is making

Blanche framed the registrations around pain treatment rather than around cannabis commerce, and that framing is the substantive claim in the announcement. The release describes the registrations as helping "ensure broader access to chronic pain treatment," which makes federally regulated medical marijuana the administration's answer for patients whose physicians have already authorized cannabis in states where that is legal.

The release makes no claim about how well cannabis treats pain, and it does not say whether registered dispensaries will have to report clinical or utilization data. What registration changes is legal exposure: a dispensary that was lawful under state law and formally illegal under federal law now holds a federal credential, subject to federal inspection and recordkeeping rather than to the threat of prosecution.

What the order leaves untouched

The order covers defined medical marijuana activities only. It does not authorize recreational sales, and marijuana outside its scope stays on Schedule I. Nothing in the release extends to insurance coverage, to dosing standards, to product testing or to the state-by-state patchwork that decides who may buy cannabis and on what certification.

The broader question of rescheduling marijuana — moving the plant itself to a lower tier — is being handled in a separate administrative proceeding, DEA said. That case was frozen on September 29 when the agency's chief administrative law judge, Derek C. Julius, stayed it to weigh a Government Accountability Office report finding that the DEA and the Food and Drug Administration lack written procedures for how they schedule drugs, as earlier coverage described. Friday's registrations do not resolve that proceeding; they route around it.

The treatment side of the ledger

For addiction treatment providers, the announcement lands on uncomfortable ground. Marijuana is the second most common substance use disorder in the country after alcohol: the 2025 National Survey on Drug Use and Health, released by the Substance Abuse and Mental Health Services Administration, counted 19.3 million people with marijuana use disorder among 44.6 million Americans with any substance use disorder, as reported here in July. A federally registered retail network is also a federally registered distribution network, and the release says nothing about how registrants will be monitored for diversion, potency or sales to people with a cannabis use disorder.

The order's compliance architecture is where that question will be answered. DEA listed security, recordkeeping and inventory controls as federal requirements layered on top of state licensure, and the manufacturers' phase — which the release says requires facility inspections, production controls and quota determinations — carries the heaviest set of requirements in the document. People seeking help for cannabis or other substance use can find treatment programs and medication-assisted treatment nationwide.

For now the practical effect is narrow and concrete: more than 900 storefronts in seven states can describe themselves as federally registered, and the next phase of applications will show whether the framework scales or stalls on the manufacturers' side of the supply chain.